What SGA is FDA approved for schizophrenia in individuals aged 10 and older?

Ziprasidone is indeed FDA approved for the treatment of schizophrenia in individuals aged 10 and older. This approval reflects its established efficacy in treating the symptoms of schizophrenia in both adult and pediatric populations.

As a second-generation antipsychotic (SGA), ziprasidone works primarily by blocking dopamine D2 receptors and serotonin 5-HT2A receptors, which helps to alleviate both positive and negative symptoms associated with schizophrenia. The advantages of using ziprasidone include a favorable side effect profile, particularly its lower propensity for causing metabolic syndrome compared to some other antipsychotics.

Clozapine, while very effective for treatment-resistant schizophrenia, is not approved for use in children and adolescents under 18 due to its association with severe side effects like agranulocytosis. Asenapine and olanzapine also have specific age restrictions or lack comparable efficacy data in the pediatric population, which is why ziprasidone stands out as the only appropriate choice in this question.